Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Antonia(Moffitt Cancer Center), Emiliano Calvo(South Texas Accelerated Research Therapeutics)
Cited by 1,252
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Soft Tissue Sarcoma
|Journal of the National Comprehensive Cancer Network|2010|167
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
|Journal for ImmunoTherapy of Cancer|2022|140